Ebastine is a second-generation histamine H1 receptor antagonist that is used to attenuate allergic inflammation. Ebastine was shown to significantly increase the proliferation of HFDPC (human follicle dermal papilla cells)[3]. Ebastine is a well-established second generation oral H1-antihistamine that is administered once daily at a dose of 10 - 20 mg and is available both as a standard tablet and as a fast-dissolving tablet that disintegrates in the mouth. Ebastine has been shown to relieve symptoms in patients with allergic rhinitis or urticaria in multiple clinical trials. Ebastine is generally well tolerated at recommended doses[4]. Pooled data from clinical efficacy trials of ebastine 1 - 30 mg/day administered for 2 - 3 weeks showed no clinically relevant cardiac effects as assessed by serial electrocardiographs and Holter monitoring[5]. Ebastine 10 mg daily is a well tolerated and effective treatment for allergic rhinitis and chronic idiopathic urticaria[6]. Ebastine 20 mg/day is indicated in patients with moderate and severe allergic symptoms, it has no relevant effects on the psychomotor performance[7].
Korea, Republic of
... 展开 >>
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center
Seoul, Dongjak-Gu, Korea, Republic of, 156-707 收起 <<
Korea, Republic of
... 展开 >>
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center
Seoul, Dongjak-Gu, Korea, Republic of, 156-707 收起 <<
搜索
